If you suffer from post-traumatic stress disorder (PTSD), as so many veterans in the US do, you may have caught word of the transformative relief certain psychedelic substances can provide. After all, The New York Times recently published an extended report highlighting the standout success ayahuasca, in particular, has proven to deliver to struggling military personnel.
Ayahuasca is a brew made from the leaves of the Psychotria Viridis shrub along with the stalks of the Banisteriopsis caapi vine. Its ritual consumption is deeply rooted in the spiritual traditions of many indigenous groups of the Upper Amazon. More recently, veterans suffering with PTSD are discovering that the transformations ayahuasca enact upon the brain offer relief even when other methods of healing have failed. In response, more than 140 ayahuasca retreat centers have sprung up around Latin America.
While legal in many countries, federal US law continues to prohibit ayahuasca use or cultivation as the brew contains N,N-Dimethyltryptamine (DMT), a Schedule 1 substance. Nonetheless, numerous religious groups have been granted special permission for ceremonial use.
Ayahuasca is not the only psychedelic medicine with proven potential to relieve PTSD and other mental health afflictions, however, and it is far from the only one gaining increasing legality worldwide. A 2018 phase 2 trial conducted at an outpatient psychiatric clinic in the USA and published in the British journal The Lancet Psychiatry saw PTSD in veterans significantly decrease when treated with 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. This and similar research has led the US Food and Drug Administration (FDA) to extend expanded access permission to the treatment, thereby making it accessible (albeit with limitations) to those in greatest need.
Esketamine, a medicine related to the more well-known ketamine and a proven source of relief for PTSD, has pushed things further. In 2019, the FDA followed counterpart organizations in Germany, Austria, Denmark, and Finland, among other European nations, in making esketamine the first psychedelic substance to gain full legal approval for therapeutic use. This is a true breakthrough as it means many folks who have otherwise failed to find relief from PTSD and other crippling afflictions gain a sliver of hope.
Alleviant Health Centers is invested in providing innovative and effective relief to those who have suffered most in service to our communities. For this reason, we offer first responders, military, or veterans a 10% discount on ketamine infusion treatment for PTSD and severe depression. If you have long-suffered with either of these ailments, we would be happy to talk about how our breakthrough treatment approach is changing peoples’ lives.